Lucia Beviglia, Ph.D., is director of cancer pharmacology in SRI Biosciences' Center for Cancer and Metabolism. Bevigilia is an experienced investigator, specializing in cancer cell biology, immunology, hematology, pharmacology, drug discovery, and preclinical drug development. She is skillful in the design, development, validation, and execution of a broad range of in vitro, in vivo, and ex vivo models to evaluate efficacy of clinical candidates and anticancer agents, and to analyze biomarkers.
Beviglia's expertise includes angiogenic and novel experimental models of cancer metastasis, and humanized tumor assays utilizing known and new sensitive imaging methods of detection.
Prior to joining SRI in 2013, Beviglia held senior scientific positions with OncoMed Pharmaceuticals, Corgentech, and Celera. She received her Ph.D. from the University of Perugia, Italy, and held postdoctoral scientist and fellowship positions at the University of North Carolina, University of California, San Francisco, Temple University, Mario Negri Institute, Milan and Santa Maria Imbaro (Italy).